ROVI lays the foundations for its future growth: it forecasts that its contract manufacturing business sales will double by 2030.
- ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase in its contract manufacturing business sales.
- The company will reinforce its current position as one of the major global leaders in the fill and finish of injectables after expanding its installed capacity.
- ROVI expects the specialty pharmaceutical division to grow annually by a low-single-digit percentage in the period from 2024 to 2030, with Okedi® as the primary growth driver.
- The company plans to commence the next phases of the clinical development of Letrozole SIE and three-monthly risperidone.
You can watch the presentation of the Capital Markets Day ROVI 2025 in this video.